ArticlePloS one2024

Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol.

Mohammadreza Eslami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.